title: [Thrombotic thrombocytopenic purpura associated with interferon therapy in a HIV and HCV co-infected woman].
abstract: BACKGROUND
  Causes of acquired thrombotic thrombocytopenic purpura (TTP) are multiple and rarely iatrogenic.
  
  
  METHODS
  A 40-year-old, HIV and hepatitis C virus co-infected woman was treated with interferon and ribavirine and developed a TTP confirmed by the presence of anti-ADAMTS 13 antibodies. The outcome was favourable when treatment was discontinued and rituximab infusion administered.
  
  
  CONCLUSIONS
  The occurrence of anemia and thrombocytopenia in patients treated with interferon and ribavirine is not always related to direct toxicities of these treatments. The ADAMS 13 testing may help the clinician to diagnose iatrogenic acquired TTP.
authors.affiliation: Service de médecine interne et maladies infectieuses, hôpital Saint-André, CHU de Bordeaux, 1, rue Jean-Burguet, 33075 Bordeaux cedex, France.
authors.forename: C
authors.initials: C
authors.lastname: Michaux
authors.forename: D
authors.initials: D
authors.lastname: Randrianasolo
authors.forename: M-A
authors.initials: MA
authors.lastname: Vandenhende
authors.forename: M
authors.initials: M
authors.lastname: Hessamfar
authors.forename: P
authors.initials: P
authors.lastname: Morlat
authors.forename: F
authors.initials: F
authors.lastname: Bonnet
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D060085:Coinfection / Q000188:drug therapy; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D015497:HIV-1; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*; D011697:Purpura, Thrombotic Thrombocytopenic / Q000139:chemically induced* / Q000175:diagnosis; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a
keywords: Interferon; Interféron; Purpura thrombotique thrombocytopénique; Thrombotic thrombocytopenic purpura